Publications by authors named "R Amatya"
Geospatial distribution of Hepatitis E seroprevalence in Nepal, 2021.
PLoS Negl Trop Dis
December 2024
Background: Hepatitis E virus (HEV) causes acute jaundice and poses an important public health problem in low- and middle-income countries. Limited surveillance capacity and suboptimal access to diagnostics leads to under-reporting of HEV infections in affected countries, including Nepal. Serum antibodies against HEV are indicative of past infection.
View Article and Find Full Text PDFBackground: Gold nanoparticles (NPs) have drawn great attention in the area of biomedical research with their relatively safe and versatile properties. This study aimed to synthesize long-lasting exendin-4-coated gold NPs (EX-ABD-AFF-GoldNPs) and evaluate their anti-diabetic effects in vivo.
Methods: In the present study, EX-ABD-AFF-GoldNPs were synthesized using a simple one-step aqueous reduction method.
Article Synopsis
- ESC is an effective anti-diabetic peptide but has a short plasma life limiting its use, prompting researchers to create a longer-lasting version called SUMO-3×ESC-ABD.
- This new fusion protein, produced from E. coli, shows low toxicity and significantly improved control of hyperglycemia and non-alcoholic fatty liver disease (NAFLD) in laboratory settings.
- In animal studies, SUMO-3×ESC-ABD had a plasma half-life 427 times longer than ESC, leading to extended therapeutic effects and improvements in overall health indicators, such as blood glucose levels and body weight.
Background: The emergence of Methicillin-resistant Staphylococcus aureus and its ability to confer cross-resistance to macrolide-lincosamide-streptogramin B has complicated the treatment against it. Gene-based studies among phenotypic methicillin-resistant isolates with inducible resistance to clindamycin are less available in Nepal. This work was undertaken to detect the mecA and erm genes among such phenotypes isolated from clinical samples.
View Article and Find Full Text PDFNonalcoholic fatty liver disease (NAFLD) has become globally prevalent and is the leading cause of chronic liver disease. Although NAFLD is reversible without medical intervention in the early stage, the condition could be sequentially worsened to nonalcoholic steatohepatitis (NASH) and, eventually, cirrhosis and hepatic cancer. The progression of NAFLD is related to various factors such as genetics, pre-disposed metabolic disorders, and immunologic factors.
View Article and Find Full Text PDF